ACB AURORA CANNABIS INC IFRS
Medicinal Chemicals & Botanical Products · Nasdaq · SEC CIK 1683541 · Reporting currency CAD · Fiscal year ends 03/31
Financial factors as of 2022-06-30 (FY2022), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY-9.8%
TTM net income YoY-148.2%
TTM EPS YoY-94.9%
Revenue 3-yr CAGR-3.4%
Net income 3-yr CAGR—
Margins
Gross margin9.6%
Operating margin-104.6%
Net margin-776.0%
FCF margin-64.4%
EBITDA margin-82.6%
Returns
ROE-127.3%
ROA-93.1%
ROIC (approx.)-19.9%
Asset turnover0.12x
Leverage & solvency
Liabilities / assets38.9%
Debt / equity0.00x
Current ratio5.69x
Interest coverage-3.22x
Cash quality & payout
Operating cash flow / net income0.06x
Accruals ratio-87.1%
Payout ratio—
Capex / revenue14.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: CAD | FY2025*2025-03-31 | FY2024*2024-03-31 | FY20222022-06-30 | FY20212021-06-30 | FY20202020-06-30 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | 343.29M | 269.64M | 221.34M | 245.25M | 268.70M |
| Gross profit | 187.61M | 131.73M | 21.23M | -21.56M | -19.93M |
| R&D expense | 3.68M | 3.57M | 10.39M | 11.45M | 26.03M |
| SG&A expense | 97.26M | 91.33M | 175.24M | 174.63M | 196.36M |
| Operating income | 4.95M | -45.10M | -231.45M | -282.82M | -465.78M |
| Interest expense | 8.42M | 13.80M | 71.81M | 66.44M | 76.11M |
| Pretax income | 20.38M | -57.64M | -1.72B | -699.80M | -3.34B |
| Income tax | 4.62M | -554,000 | -2.14M | -6.32M | -82.23M |
| Net income | 1.59M | -69.33M | -1.72B | -692.01M | -3.28B |
| EBITDA | 14.03M | -33.12M | -182.85M | -233.64M | -398.21M |
| EPS (basic) | 0.04 | -1.52 | -7.99 | -4.10 | -33.93 |
| EPS (diluted) | 0.04 | -1.52 | -7.99 | -4.10 | -33.93 |
| Weighted avg. shares (diluted) | 55.62M | 43.22M | — | — | — |
| Balance sheet | |||||
| Cash & equivalents | 137.92M | 136.09M | 437.81M | 421.46M | 162.18M |
| Short-term investments | 554,000 | 4.04M | — | — | — |
| Receivables | 42.47M | 45.41M | 46.99M | 56.26M | 54.11M |
| Inventory | 187.93M | 143.60M | 116.10M | 117.47M | 135.88M |
| Current assets | 478.33M | 426.61M | 745.12M | 665.89M | 417.51M |
| PP&E, netmay include right-of-use assets (IFRS) | 268.11M | 294.32M | 233.47M | 606.09M | 946.38M |
| Goodwill | 43.87M | 43.18M | 0 | 887.74M | 927.88M |
| Intangibles | 45.16M | 40.85M | 70.70M | 367.45M | 412.27M |
| Total assets | 852.67M | 838.67M | 1.08B | 2.60B | 2.78B |
| Current liabilities | 110.86M | 124.62M | 130.86M | 116.38M | 272.26M |
| Short-term debt | 2.30M | 52.36M | 0 | 0 | 113.92M |
| Long-term debt | 40.19M | 4.90M | 0 | — | 83.70M |
| Total debt | 42.49M | 57.26M | 0 | — | 197.62M |
| Total liabilities | 244.07M | 236.80M | 422.00M | 567.03M | 656.70M |
| Shareholders' equity | 567.17M | 559.77M | 661.84M | 2.04B | 2.15B |
| Net debt | -95.43M | -78.84M | -437.81M | — | 35.44M |
| Cash flow statement | |||||
| Operating cash flow | 16.00M | -68.51M | -110.27M | -210.58M | -342.14M |
| Capital expenditure | — | — | 32.21M | 53.08M | — |
| Free cash flow | — | — | -142.48M | -263.66M | — |
| Investing cash flow | -14.33M | -3.36M | -36.17M | -26.91M | -245.43M |
| Financing cash flow | -116,000 | -47.92M | 147.78M | 521.95M | 582.56M |
| Depreciation & amortization | 9.08M | 11.98M | 48.60M | 49.17M | 67.57M |
| Stock-based compensation | 11.52M | 12.72M | 13.76M | 20.24M | 59.18M |
Free plan shows the latest 5 periods; Pro shows all 7 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· Amounts are in the company's reporting currency, CAD, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.